| Members |
targetComponentId |
| Acute pelvic cellulitis |
Acute pelvic inflammatory disease |
| Acute pharyngitis, NOS |
Acute pharyngitis |
| Acute polyarticular juvenile rheumatoid arthritis |
Acute polyarticular juvenile idiopathic arthritis (disorder) |
| Acute polyarticular juvenile rheumatoid arthritis |
Acute polyarticular juvenile idiopathic arthritis (disorder) |
| Acute pulmonary edema |
Acute pulmonary edema |
| Acute reaction to foreign substance left during procedure NOS |
Acute reaction to foreign substance left during procedure |
| Acute respiratory distress, NEC |
Acute respiratory distress (finding) |
| Acute rheumatic heart disease, NOS |
Acute rheumatic heart disease |
| otite moyenne purulente aiguë causée par une autre maladie |
Acute suppurative otitis media |
| Acute yellow atrophy of liver during pregnancy |
Necrosis of liver of pregnancy |
| Acyclovir 200mg dispersible tablet |
Aciclovir 200 mg oral tablet |
| Acyclovir 400mg dispersible tablet |
Aciclovir 400 mg oral tablet |
| Acyclovir 800mg dispersible tablet |
Aciclovir 800 mg oral tablet |
| Addiction |
Addiction |
| Addison's disease, NOS |
Addison's disease |
| conditions générales additionnelles à propos du patient |
Clinical finding (finding) |
| intervention préopératoire additionnelle effectuée par un anesthésiste |
Preoperative procedure |
| traitement préopératoire additionnel effectué par un anesthésiste |
Preoperative procedure |
| Adductor digiti minimi muscle of hand |
Structure of abductor digiti minimi muscle of hand (body structure) |
| grade histologique d'un adénocarcinome et d'un carcinome épidermoïde |
Histologic grade of neoplasm (observable entity) |
| adénocarcinome |
Adenocarcinoma (morphologic abnormality) |
| adénocarcinome non sous-typé de haut grade |
High grade adenocarcinoma (morphologic abnormality) |
| adénocarcinome non sous-typé de grade intermédiaire |
Intermediate grade adenocarcinoma (morphologic abnormality) |
| Adenocarcinoma, no subtype, low grade |
Low grade adenocarcinoma (morphologic abnormality) |
| Adenofibroma, no International Classification of Diseases for Oncology subtype |
Benign adenofibroma (morphologic abnormality) |
| Adenoma, no subtype |
Adenoma (morphologic abnormality) |
| adénosine 3 mg/mL, flacon de 10 mL de solution pour injection |
Product containing precisely adenosine 3 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Adhesiolysis - action |
Dissection - action |
| Adhesive sealing |
Sealing |
| Adie's pupil |
Tonic pupillary reaction |
| Adjustment of external splintage |
Adjusting of splint |
| Adjustment reaction in infancy |
Adjustment reaction in infancy (disorder) |
| Adjustment reaction of adolescence |
Adjustment reaction of adolescence (disorder) |
| Adjustment reaction of adult life |
Adjustment reaction of adult life (disorder) |
| Adjustment reaction of childhood |
Adjustment reaction of childhood (disorder) |
| Adjustment reaction of late life |
Adjustment reaction of late life (disorder) |
| administration |
Introduction procedure (procedure) |
| Administration |
Introduction procedure (procedure) |
| Administration |
Introduction procedure (procedure) |
| Administration |
Introduction procedure (procedure) |
| Administration of RhD immune globulin |
Administration of human anti-D immunoglobulin (procedure) |
| Administration of RhD immune globulin declined |
Administration of human anti-D immunoglobulin declined |
| administration de médicaments et de solutions sur ordonnance |
Administration of medication |
| administration de médicaments prescrits basée sur les résultats de la gazométrie artérielle |
Administration of medication |
| Administration of skin test by nurse |
Skin test |
| administration d'une substance |
Introduction procedure (procedure) |
| Administration of syntometrine |
Administration of ergometrine and oxytocin |
| Administration of therapeutic medication |
Administration of medication |
| administration d'une substance thérapeutique |
Administration of medication |
| Administration of therapeutic substance |
Administration of medication |
| Administration of vaccine product containing only Human papillomavirus 9 antigen |
Administration of Human papillomavirus 6, 11, 16, 18, 31, 33, 45, 52 and 58 vaccine |
| Administrative and indirect care procedures |
Procedure |
| Adrenal cortex agent |
Adrenal cortex hormone |
| Adrenal cortical adenoma - category |
Benign adrenal cortical adenoma (morphologic abnormality) |
| Adrenal cortical adenoma, no International Classification of Diseases for Oncology subtype |
Benign adrenal cortical adenoma (morphologic abnormality) |
| Adrenal hormone agent |
Adrenal hormone |
| Adrenaline 0.5% eye drops |
Adrenaline (as adrenaline acid tartrate) 500 microgram/mL eye solution |
| Adrenaline 1:1000 500micrograms/0.5mL injection |
Adrenaline 1 mg/mL nasal solution |
| Adult Kienbock's disease of bilateral lunate |
Progressive avascular necrosis of bilateral lunate bones (disorder) |
| maladie de l'adulte |
Disease |
| Adult periodontitis |
Chronic periodontitis |
| Adult rhabdomyoma |
Adult cellular rhabdomyoma (morphologic abnormality) |
| Adult type granulosa cell tumor of testis |
Adult type granulosa cell tumor of uncertain behavior (morphologic abnormality) |
| Advancement of flap graft |
Reconstruction using local advancement flap (procedure) |
| Adverse effect of oral diphosphonate |
Adverse reaction caused by bisphosphonate (disorder) |
| Adverse effects NEC |
Adverse reaction (disorder) |
| Adverse effects NOS |
Adverse reaction (disorder) |
| Adverse reaction caused by acidifying agent |
Adverse reaction to drug |
| Adverse reaction caused by alkalizing agents |
Adverse reaction to drug |
| Adverse reaction caused by carbromal derivative |
Adverse reaction to carbromal |
| Adverse reaction caused by drug primarily acting on the smooth and skeletal muscles and respiratory system |
Adverse reaction to drug |
| Adverse reaction caused by intravenous diphosphonate |
Adverse reaction caused by bisphosphonate (disorder) |
| Adverse reaction caused by liver preparations and other antianemic agents |
Adverse reaction to drug |
| effet indésirable d'une substance |
Adverse reaction (disorder) |
| Adverse reaction to CNS depressants and anesthetics |
Adverse reaction to drug |
| Adverse reaction to agent affecting blood constituents NOS |
Adverse reaction to drug |
| Adverse reaction to agent affecting blood constituents NOS |
Adverse reaction to drug |
| Adverse reaction to agents primarily affecting blood constituents |
Adverse reaction to drug |
| Adverse reaction to agents primarily affecting blood constituents |
Adverse reaction to drug |
| Adverse reaction to antiasthmatic NOS |
Adverse reaction to drug |
| Adverse reaction to anticonvulsant and antiparkinsonism drugs NOS |
Adverse reaction to drug |
| Adverse reaction to anticonvulsants and anti-parkinsonism drugs |
Adverse reaction to drug |
| Adverse reaction to antiparkinsonism drug |
Adverse reaction to drug |
| Adverse reaction to antiparkinsonism drugs NOS |
Adverse reaction to drug |
| Adverse reaction to bromine compound |
Adverse reaction caused by bromine and/or bromine compound (disorder) |
| Adverse reaction to cardiac glycoside |
Adverse reaction to Digitalis glycoside |
| Adverse reaction to cardiac glycosides NOS |
Adverse reaction to Digitalis glycoside |
| Adverse reaction to central nervous system depressant |
Adverse reaction to drug |
| Adverse reaction to central nervous system muscle-tone depressants NOS |
Adverse reaction to drug |
| Adverse reaction to clomocycline sodium |
Adverse reaction to clomocycline |
| Adverse reaction to clorazepate dipotassium |
Adverse reaction to clorazepate |
| réaction indésirable à un composant d'un vaccin contenant l'antigène ou l'ARNm du SRAS-Cov-2 |
Adverse reaction to COVID-19 vaccine |
| Adverse reaction to dental drugs topically applied |
Adverse reaction to drug |
| Adverse reaction to drug primarily affecting the autonomic nervous system NOS |
Adverse reaction to drug |
| Adverse reaction to drug primarily affecting the cardiovascular system NOS |
Adverse reaction to drug |
| Adverse reaction to drug primarily affecting the cardiovascular system NOS |
Adverse reaction to drug |
| Adverse reaction to drugs primarily affecting autonomic nervous system |
Adverse reaction to drug |
| Adverse reaction to drugs primarily affecting gastrointestinal system |
Adverse reaction to drug |
| Adverse reaction to drugs primarily affecting gastrointestinal system |
Adverse reaction to drug |
| Adverse reaction to drugs primarily affecting skin and mucous membrane, ophthalmological, otorhinolaryngological and dental drugs |
Adverse reaction to drug |
| Adverse reaction to drugs primarily affecting the cardiovascular system |
Adverse reaction to drug |
FHIR